Global Neurology Clinical Trials Market Executive Summary
Many large pharmaceutical companies have their attention focused on the field of neuroscience. Drug producers are now focusing on other neurological conditions including spinal muscular atrophy after successfully treating Alzheimer's disease. The market for neurology clinical trials is developing, which is largely attributed to the rise in neurological diseases including dementia, stroke, and peripheral neuropathy as well as rising R&D expenditures in neurological research.
Market Size and Key Findings
The Global Neurology Clinical Trials Market size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.
Global Neurology Clinical Trials Market Size (In USD Bn)
(2021-2030F)
Market Dynamics
Market Growth Drivers Analysis
The market for neurology clinical trials is being driven by the increased frequency of neurological illnesses and the existence of several companies in clinical trials.
Competitive Landscape
Key Players
The prominent players operating in this market include IQVIA; Novartis; Covance; Medpace; Charles River Laboratories; Syneous Health; Icon PLC; GlaxoSmithKline; Aurora Healthcare; Biogen
TABLE OF CONTENT
1. Report Description of the Global Neurology Clinical Trials Market
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. Global Neurology Clinical Trials Market Executive Summary
